210
Participants
Start Date
March 16, 1998
Primary Completion Date
August 24, 2017
Study Completion Date
August 24, 2017
Fludarabine
Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
Novantrone
Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
Decadron
Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Rituximab
Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
Interferon
Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
Doxorubicin
25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
Vincristine
.7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
Bleomycin
5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
Cyclophosphamide
750 mg/m\^2 IV Day 2 of 1st Sequence.
Etoposide
40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
Cisplatin
25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
Ara-C
1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
Methyl-Prednisolone
500 mg IV Days 1 through 5 of 2nd Sequence.
Procarbazine
100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
Prednisone
100 mg PO Days 1 through 5 of 3rd Sequence.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Genentech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER